Applied Clinical Trials
Proving a biosimilar's pharmacokinetic 'equivalence' requires adherence to several unique factors.
Yvonne Moores, Executive Vice President, Operations (SRBU), Quanticate
Advertisement
Articles by Yvonne Moores, Executive Vice President, Operations (SRBU), Quanticate
Advertisement
Latest Updated Articles
Demonstrating Biosimilarity: PK ConsiderationsOctober 1st 2014
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
5